



US007563779B2

(12) **United States Patent**  
**Henderson et al.**

(10) **Patent No.:** **US 7,563,779 B2**  
(45) **Date of Patent:** **\*Jul. 21, 2009**

(54) **L-ERGOTHIONEINE, MILK THISTLE, AND S-ADENOSYLMETHIONINE FOR THE PREVENTION, TREATMENT AND REPAIR OF LIVER DAMAGE**

(75) Inventors: **Todd R. Henderson**, Jarrettsville, MD (US); **Barbara E. Corson**, Fawn Grove, PA (US)

(73) Assignee: **Nutramax Laboratories**, Edgewood, MD (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 631 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/037,332**

(22) Filed: **Jan. 19, 2005**

(65) **Prior Publication Data**

US 2005/0129785 A1 Jun. 16, 2005

**Related U.S. Application Data**

(63) Continuation of application No. 10/153,877, filed on May 24, 2002, now Pat. No. 6,863,906, which is a continuation of application No. 09/731,719, filed on Dec. 8, 2000, now abandoned, which is a continuation-in-part of application No. 09/256,352, filed on Feb. 24, 1999, now Pat. No. 6,555,141.

(60) Provisional application No. 60/076,347, filed on Feb. 27, 1998.

(51) **Int. Cl.**

**A61K 35/78** (2006.01)  
**A61K 31/70** (2006.01)

(52) **U.S. Cl.** ..... **514/46**; 514/398; 514/399; 424/725

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

- 3,882,228 A 5/1975 Boncey et al.
- 3,887,700 A 6/1975 Boncey et al.
- 4,061,765 A 12/1977 Madaus et al.
- 4,100,160 A 7/1978 Walser
- 4,296,127 A 10/1981 Walser
- 4,314,989 A 2/1982 Rosen
- 4,994,457 A 2/1991 Crawford et al.
- 5,084,482 A 1/1992 Hirsch et al.
- 5,137,712 A 8/1992 Kask et al.
- 5,288,503 A 2/1994 Wood et al.
- 5,474,757 A 12/1995 Yang

- 5,569,458 A 10/1996 Greenberg
- 6,255,295 B1 7/2001 Henderson et al.
- 6,271,213 B1 8/2001 Henderson et al.
- 6,555,141 B1\* 4/2003 Corson et al. .... 424/725
- 6,583,123 B2 6/2003 Henderson et al.
- 6,863,906 B2\* 3/2005 Henderson et al. .... 424/725

**OTHER PUBLICATIONS**

- Adachi et al., "The Effects of S-adenosylmethionine on Intrahepatic Cholestasis," *Jpn. Arch. Int. Med.*, 33(6): 185-192 (1986).
- Akanmu, D. et al., "The Antioxidant Action of Ergothioneine," *Archives of Biochemistry and Biophysics*, 288(1): 10-16 (1991).
- Alvaro, D. et al., S-adenosylmethionine (S-AdoMet) protects against acute ethanol hepatotoxicity in the isolated perfused rat liver (IPRL) with no effect on trancytosis, *EASL, Journal of Hepatology*, 21(Suppl. 1): S81 (1994).
- Arias, I.M. and Kinne, R., On the pathophysiology and reversibility of intrahepatic cholestasis, *Clinical Research*, 32:548A (1984).
- Aruoma, O.I. et al., "Antioxidant action of ergothioneine: assessment of its ability to scavenge peroxynitrite," *Biochem. Biophys. Res. Commun.* 231(2): 389-91, abstract (Feb. 13, 1997).
- Baldessarini, R., "Neuropharmacology of S-Adenosyl Methionine," *American Journal Medicine*, 83(5A): 95-103 (1987).
- Barrio, E. et al., Comparative effect of nifedipine and S-adenosylmethionine, singly and in combination on experimental rat liver cirrhosis, *Life Sciences*, 52:PL 217-220 (1993).
- Belli, D.C. et al., S-adenosylmethionine prevents total parenteral nutrition-induced cholestasis in the rat, *Journal of Hepatology*, 21: 18-23 (1994).
- Bortolini, M. et al., Multicentre Survey of the Prevalence of Intrahepatic Cholestasis in 2520 Consecutive Patients with Newly Diagnosed Chronic Liver Disease, *Drug Investigation*, 4(Suppl. 4): 83-89 (1992).

(Continued)

*Primary Examiner*—Traviss C McIntosh, III  
(74) *Attorney, Agent, or Firm*—Arent Fox LLP

(57) **ABSTRACT**

This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising two or more compounds selected from the group consisting of S-adenosylmethionine, L-ergothioneine, and a substance selected from the group consisting of constituents of Milk thistle (*Silybum marianum*), silymarin and active components of silymarin, whether naturally, synthetically, or semi-synthetically derived, and to methods of preventing and treating liver disease and of repairing damaged liver tissue. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof.

**19 Claims, 6 Drawing Sheets**